Objective: To systematically review evidence bearing on the management of patients with
amyotrophic lateral sclerosis (ALS). Methods: The authors analyzed studies from 1998 to 2007 …

Background Thymectomy has been a mainstay in the treatment of myasthenia gravis, but
there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial …

Background Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal
death in experimental models. The efficacy and safety of a combination of the two compounds …

Background Approximately 90% of persons with amyotrophic lateral sclerosis (ALS) have
the sporadic form, which may be caused by the interaction of multiple environmental factors …

We report 11 patients with multifocal acquired demyelinating sensory and motor (MADSAM)
neuropathy, defined clinically by a multifocal pattern of motor and sensory loss, with nerve …

Objective Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable,
neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing …

Inclusion body myositis, polymyositis, and dermatomyositis are three distinct categories of
inflammatory myopathy. Some authorities commented on the selective early weakness of the …

Background The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving
Prednisone (MGTX) showed that thymectomy combined with prednisone was superior …

An orally administered, fixed‐dose coformulation of sodium phenylbutyrate‐taurursodiol (PB‐TURSO)
significantly slowed functional decline in a randomized, placebo‐controlled, …

Objective To compare the effect of riluzole on median survival in population studies of patients
with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials. Methods: Two …